|
Title
|
|
|
|
Real-life after sacral nerve modulation implantation : rate, reasons, and risk factors for mid-term follow-up discontinuation = Vie réelle après l’implantation d’une neuromodulation sacrée : taux, raisons et facteurs de risque d’interruption du suivi à mi-parcours
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Objectives. - To evaluate follow-up after implantation of a sacral nerve modulation implantable pulse generator (IPG) and to investigate the reasons and risk factors for follow-up discontinuation. Materials and methods. - All patients who underwent an IPG implantation to treat lower urinary tract symptoms between 2014-2019 within 6 hospital centers located in the district of "Hauts-de-France" (France) were systematically called during the year 2020 for a standardized (tele)consultation. Patients were divided into 3 distinct profiles according to the regularity of their 5-year postoperative follow-up: "Regular follow-up", "Irregular follow-up" and "Lost to follow-up". The primary outcome was the change in the annual proportion of the 3 follow-up profiles over the 5 years following IPG implantation. As secondary outcomes we described the reasons reported for follow-up discontinuation and looked for risk factors associated with. Results. - Overall, 259 patients were included. At the time of data collection, after a mean follow-up of 28.4 (+/- 19.8) months, 139 patients (53.7%) had a "Regular follow-up", 54 (20.8%) had an "Irregular follow-up" and 66 (25.5%) were "Lost to follow-up". The proportion of patients with a "Regular follow-up" decreased year by year, representing only 46.2% of patients at five-years. 175 patients (67.6%) underwent a standardized (tele)consultation. In multivariate analysis, only "lack of knowledge of the follow-up protocol" was statistically associated with follow-up discontinuation (OR = 5.16; 95% CI [2.12-13.57]). Conclusion. - The proportion of patients followed up after IPG implantation decreased steadily over the years, often related to a lack of therapeutic education. Level of evidence.- 4. (c) 2023 Elsevier Masson SAS. All rights reserved. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Progrès en urologie. - Paris
| |
|
Publication
|
|
|
|
Paris
:
2023
| |
|
ISSN
|
|
|
|
1166-7087
| |
|
DOI
|
|
|
|
10.1016/J.PUROL.2023.10.004
| |
|
Volume/pages
|
|
|
|
33
:17
(2023)
, p. 1047-1061
| |
|
ISI
|
|
|
|
001123328900001
| |
|
Pubmed ID
|
|
|
|
37949799
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|